Entera Bio (ENTX) EBT (2019 - 2026)
Entera Bio's (ENTX) quarterly EBT came in at -$3.6 million in Q1 2026, down 37.88% YoY from -$5.8 million in Q1 2025, and down 15.07% on a QoQ basis from -$3.1 million in Q4 2025.
Entera Bio (ENTX) EBT (2019 - 2026) Analysis & Trends
Entera Bio (ENTX) has 8 years of EBT data on file, last reported at -$3.6 million in Q1 2026.
- Quarterly EBT fell 37.88% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.9 million (down 23.94% YoY) and the FY2025 annual result came in at -$11.4 million, down 20.07% from the prior year.
- EBT retreated to -$3.6 million in Q1 2026, from -$3.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$2.0 million in Q4 2023 to a low of -$3.8 million in Q1 2022.
- A 5-year average of -$2.8 million and a median of -$2.7 million in 2025 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT plunged 64.11% — and 2023, when it jumped 42.23%.
- Tracing ENTX's EBT over 5 years: stood at -$3.1 million in 2022, then jumped by 35.25% to -$2.0 million in 2023, then retreated by 17.49% to -$2.3 million in 2024, then tumbled by 33.87% to -$3.1 million in 2025, then declined by 15.07% to -$3.6 million in 2026.
- The last three EBT figures came in at -$3.6 million (Q1 2026), -$3.1 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Entera Bio | 162.20 Mn | 150.89 Mn | - | -4.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.58 Mn |
| Mar 31, 2026 | -3.61 Mn |
| Dec 31, 2025 | -3.14 Mn |
| Sep 30, 2025 | -3.43 Mn |
| Jun 30, 2025 | -2.73 Mn |
| Mar 31, 2025 | -2.62 Mn |
| Dec 31, 2024 | -2.34 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -2.44 Mn |
| Mar 31, 2024 | -2.06 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Sep 30, 2023 | -2.35 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Mar 31, 2023 | -2.19 Mn |
| Dec 31, 2022 | -3.08 Mn |
| Sep 30, 2022 | -2.87 Mn |
| Jun 30, 2022 | -3.19 Mn |
| Mar 31, 2022 | -3.79 Mn |
| Dec 31, 2021 | -4.12 Mn |
| Sep 30, 2021 | -3.23 Mn |